PregnancyNCT07412925
Impact Tourniquet Conservative Placenta Accreta Neonatal APGAR
A study testing Application Of A Tourniquet Around the lower segment of the uterus and Placenta Accreta spectrum conservative management in people with Pregnancy and Placenta Accrete Spectrum, run by Kasr El Aini Hospital at 1 site in Egypt.
Trial summary
Placenta accreta spectrum disorder (PAS) refers to a condition where the placenta fails to separate naturally after childbirth, which can cause significant maternal and neonatal complications, including severe bleeding, leading to increased morbidity and mortality. Read more about this study
- Who is it for?
- Ages 20 to 40 years, women only
- Conditions the study is for
- Pregnancy, Placenta Accrete Spectrum, Tourniquets
- What is being tested?
- Application Of A Tourniquet Around the lower segment of the uterus and Placenta Accreta spectrum conservative management
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Apr 2025to 1 Mar 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 40 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Age: 20-40 years old.
- Pregnancy of a singleton living fetus.
- Gestational age: pregnancy completing 34 weeks or more.
- Previous one or more cesarean delivery.
- Current pregnancy complicated by Placena Accreta Spectrum Disorder candidate for conservative managment either total or partial Placenta Accreta.
- Elective termination of pregnancy. (35-37 weeks)
- Preoperative Hemoglobin ≥ 10 g/dl.
Who cannot join
- 1-Patients who refuse to participate in the study. 2-Women with history of a concomitant chronic or a pregnancy associated medical disorder eg. Gestational diabetes, hypertension, cardiac or renal disease.
- 3-Presence of a concomitant uterine pathology (eg. Uterine fibroid) 4-Premature rupture of membranes. 5-Cases misdiagnosed as placenta accreta by ultrasound preoperatively, and spontaneous full placental separation occurred intraoperative or as total/partial accreta and found to be focal accreta intraoperative.
- 6-Cases requiring preoperative blood transfusion. 7- Any fetal abnormality e.g IUGR or SGA
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
kasr Al Aini Hospitals , Faculty of medicine , Cairo University , Cairo
Cairo
Abdallah M Mousa, MD, 0020127664430, Dr_abdallahmousa@yahoo.com
About this study
Official title: Impact of Using Tourniquet in Conservative Placenta Accrete Spectrum on Neonatal APGAR Score . A Randomized Controlled Trial .
Placenta accreta spectrum disorder (PAS) refers to a condition where the placenta fails to separate naturally after childbirth, which can cause significant maternal and neonatal complications, including severe bleeding, leading to increased morbidity and mortality. According to the pathological characteristics, PAS can be classified into three categories, including placenta accreta, placenta increta, and placenta percreta. Risk factors for PAS were identified as cesarean section (CS), hysteroscopy history, in vitro fertilization and embryo transfer and placenta previa, etc. It was reported that over 90% of the PAS cases were with prior cesarean delivery. In order to reduce the morbidity and mortality caused by PAS, guidelines were released from several international societies, including the Federation of Gynecology and Obstetrics (FIGO), Royal College of Obstetricians and Gynecologists (RCOG), the American College of Obstetricians and Gynecologists (ACOG) and Society of Obstetricians and Gynecologists of Canada (SOGC) recommending comprehensive multidisciplinary team (MDT) and expertise in pelvic and abdominal surgeries are essential for patients with PAS. Antenatal diagnosis of PAS is highly advisable, which is closely associated with surgery options, bleeding management and success of uterine preservation. Current diagnostic approaches include imaging examination, PAS prenatal grading system and MDT. Severe complications of PAS (particularly in the case of PP), such as substantial hemorrhage and organ injury, are closely related to the placental position and trophoblast invasion depth. Ultrasonography and MRI are major imaging means for prenatal diagnosis. In the meantime, to preserve fertility, approaches to conservative surgical management for PAS have been developed. The purpose for conservative management of PAS patients is to reduce bleeding, avoid organ injury, preserve the uterus and maintain uterine function. As the concept of uterine preservation is accepted by more and more practitioners, conservative surgical techniques have been developed accordingly. According to the survey of the Society for Maternal-Foetal Medicine (SMFM), only 15-32% of doctors would apply conservative management for PAS cases. Due to the lack of high-quality clinical trials as well as follow-up studies, standardized surgical management for PAS has not yet been determined. There are three approaches applied to placenta management in PAS, including manual separation of placenta, one-step conservative surgery and leaving the placenta in situ. Removing the complete placenta can effectively reduce bleeding and infection and preserve the uterus. The classical "Triple-P" management was proposed in 2012, which includes perioperative placental localization, pelvic devascularization and placental non-separation with myometrial excision and uterine reconstruction. The uterine artery tourniquet has numerous advantages, including a decrease in blood loss and the number of transfused packed RBC units. The simplicity of the technique allows for residents to apply the tourniquet to decrease the bleeding and allows time until an experienced obstetrician arrives. Presently, other attempts to avoid hysterectomy include uterine compression sutures, intrauterine balloon tamponade, pelvic artery ligation, and spiral suturing of the lower uterine segment. Intrauterine balloon tamponade may increase CS scar dehiscence, uterine rupture, and infection. Best practices for these methods involve skilled surgeons and obstetricians who have detailed knowledge of pelvic artery anatomy that includes vascular variations or distortions. The Apgar score was established in 1953 as a rapid newborn assessment immediately after birth. It provides a mechanism to describe the situation of the fetus becoming a newborn. Physicians face many challenges in analyzing the fetus' transition into a baby in the delivery room, especially for premature ones. The Apgar score is usually used to analyze the newborn after birth in the delivery room briefly. Thus, the Apgar score analyzes the clinical signs in neonates, such as cyanosis, pallor, bradycardia, decreased reflex response to stimulation, hypotonia, and apnea, or breathing problems such as abnormal rate and tachypnea as quantitative data. The Apgar score is reported at 1 and 5 min after birth and repeated every 5 min up to 20 min for infants with an Apgar score <7. A peculiar step of such a surgical approach involves the ligature of newly formed vessels between the uterus and the bladder. It has been speculated that such a step may affect the newborn by reducing blood flow to the placenta. This study aimed to report the neonatal outcome of women undergoing conservative reconstructive technique for PAS.
- Conditions
- Pregnancy, Placenta Accrete Spectrum, Tourniquets, Apgar Score
- Being tested
- Application Of A Tourniquet Around the lower segment of the uterus, Placenta Accreta spectrum conservative management
- Keywords
- placenta Accrete, Tourniquet, conservative, APGAR score
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Application Of A Tourniquet Around the lower segment of the uterusProcedure or surgery
Foley catheter (20Fr) will be applied around the lower uterine segment at level lower than the placenta acting as a tourniquet The dissection of the utero-vesical fold will be extended laterally to both broad ligaments \& bilateral opening in the anterior leaflet of the broad ligament will be made. Both ureters will be identified beforehand. Foley catheter will be passed through the posterior leaflet of the left broad ligament in an avascular area, then passing the catheter back through Douglas pouch through the right broad ligament.The Foley catheter tourniquet will include both the lower uterine segment \& part of the bladder dome. supra-placental hysterotomy incision is carried out immediately after tightening the tourniquet followed by fetal extraction with immediate cord clamping (< 30 seconds).The uterus is then exteriorized, kept under upward traction so uterine vascular constriction can diminish blood loss \& the hysterotomy incision bleeding is temporarily control by towel clips
Placenta Accreta spectrum conservative managementProcedure or surgery
No tourniquet is applied around the lower uterine segment:
Same technique without adding a temporary tourniquet around the uterine artery.
| Study group | Role | What they receive |
|---|---|---|
| Tourniquet Group A | Active comparator | Foley catheter (20Fr) will be applied around the lower uterine segment at level lower than the placenta acting as a tourniquet The dissection of the utero-vesical fold will be extended laterally to both broad ligaments \& bilateral opening in the anterior leaflet of the broad ligament will be made. Both ureters will be identified beforehand. Foley catheter will be passed through the posterior leaflet of the left broad ligament in an avascular area, then passing the catheter back through Douglas pouch through the right broad ligament.The Foley catheter tourniquet will include both the lower uterine segment \& part of the bladder dome. supra-placental hysterotomy incision is carried out immediately after tightening the tourniquet followed by fetal extraction with immediate cord clamping (< 30 seconds).The uterus is then exteriorized, kept under upward traction so uterine vascular constriction can diminish blood loss \& the hysterotomy incision bleeding is temporarily control by towel clips Receives: Procedure: Application Of A Tourniquet Around the lower segment of the uterus |
| Non-Tourniquet group (B) | Placebo comparator | No tourniquet is applied around the lower uterine segment:
Same technique without adding a temporary tourniquet around the uterine artery. Receives: Procedure: Placenta Accreta spectrum conservative management |
What is being measured
The primary outcome is the main question the study is designed to answer.
Neonatal Apgar Score
This scoring system provided a standardized assessment for infants after delivery. The Apgar score comprises five components: 1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is given a score of 0, 1, or 2. Thus, the Apgar score quantitates clinical signs of neonatal depression such as cyanosis or pallor, bradycardia, depressed reflex response to stimulation, hypotonia, and apnea or gasping respirations. The score is reported at 1 minute and 5 minutes after birth for all infants, and at 5-minute intervals thereafter until 20 minutes for infants with a score less than
Measured: 1 min and 5 mins after birth for all infants , and if after 5 mins score is less than 7 , scoring will continue every 5 mins till 20 mins
Secondary outcomes (11)
Neonatal encephalopathy
Neonatal encephalopathy is a clinically defined syndrome of disturbed neurologic function in the earliest days of life in an infant born at or beyond 35 weeks of gestation, manifested by a subnormal level of consciousness or seizures, and often accompanied by difficulty with initiating and maintaining respiration and depression of tone and reflexes
Measured: Immediately after birth
Gestational age
According to American College of Obstetricians and Gynecologists, the main methods to calculate gestational age are
- Directly calculating the days since the beginning of the last menstrual period
- Early obstetric ultrasound, comparing the size of an embryo or fetus to that of a reference group of pregnancies of known gestational age (such as calculated from last menstrual periods) and using the mean gestational age of other embryos or fetuses of the same size. If the gestational age as calculated from an early ultrasound is contradictory to the one calculated directly from the last menstrual period, it is still the one from the early ultrasound that is used for the rest of the pregnancy.(21)
Measured: preoperative
Birthweight
Birthweight measured in grams.
Measured: immediately postoperative
Requirement for oxygen support
in the form of supplementary oxygen, nasal positive pressure ventilation or mechanical ventilatory support
Measured: immediately postoperative
NICU
Admission to neonatal intensive care unit (NICU) and the length of NICU stay in days.
Measured: immediately postoperative
Early Neonatal Mortality
Early neonatal mortility
Measured: one week
Operative time
the time from bladder dissection , till uterine closure
Measured: intraoperative
Incidence of bleeding
No of packed Rbcs that the patient required to be transfused according to the vital status of the patient as well as postoperative according to vital status of the patient and hemoglobin level postoperative , as well as the amount of bleeding that occured either intraoperative r postoperative
Measured: perioperative and immediately postoperative
Incidence of complications
Internal organ injury (Bladder, intestine, ureter) as well as Inadvertent injury to the pelvic vessels (eg. Injury to the ovarian vessels while inserting the tourniquet)
Measured: intraoperative
Incidence of ICU admission
ICU admission incidence
Measured: immediately postoperative and up to 48 hours
Duration of hospital stay
Usually length of hospital stay for a placenta accreta spectrum patient without icu admission around 48 hours , and if icu admission happens for 1 or 2 days then 48 more hours after discharge from icu
Measured: from 48 hours to 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Feb 2026
- Study start30 Apr 2025
- Primary completion1 Mar 2026 (estimated)
- Study completion1 Mar 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for PregnancyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- randomized control trial formed of two groups group A receiving tourniquet group B control group
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kasr El Aini Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Yassmine Amr Abd El Megid Hamouda, Kasr El Aini Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07412925
- Sponsor's protocol ID
- MD-453-2024
- Status last verified
- Feb 2026
- First submitted
- 21 Nov 2025
- Last updated
- 17 Feb 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
- Obstetrics Subgroup SoOaG, Chinese Medical Association; Maternal and Fetal Medicine Special Committee of Obstetrics and Gynecology Branch of Chinese Medical Doctor Association. Guideline for diagnosis and treatment of placenta accreta spectrum disorders. Chinese Journal of Perinatal Medicine.2023;26(08):617-627.
Jauniaux E, Kingdom JC, Silver RM. A comparison of recent guidelines in the diagnosis and management of placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021 Apr;72:102-116. doi: 10.1016/j.bpobgyn.2020.06.007. Epub 2020 Jun 27.
PubMed 32698993Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int J Womens Health. 2020 Nov 10;12:1033-1045. doi: 10.2147/IJWH.S224191. eCollection 2020.
PubMed 33204176
Study at a glance
From the registry record, last updated by the sponsor on 17 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Using Tourniquet in Conservative Placenta Accrete Spectrum on Neonatal APGAR Score . A Randomized Controlled Trial .
- ClinicalTrials.gov ID
- NCT07412925
- Acronym / sponsor ID
- MD-453-2024
- Conditions
- Pregnancy, Placenta Accrete Spectrum, Tourniquets, Apgar Score
- Keywords
- placenta Accrete, Tourniquet, conservative, APGAR score
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Kasr El Aini HospitalUniversity, hospital or other
- Study start
- 30 Apr 2025 (actual)
- Primary completion
- 1 Mar 2026 (estimated)
- Study completion
- 1 Mar 2026 (estimated)
- First posted
- 17 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Placenta accreta spectrum disorder (PAS) refers to a condition where the placenta fails to separate naturally after childbirth, which can cause significant maternal and neonatal complications, including severe bleeding, leading to increased morbidity and mortality. According to the pathological characteristics, PAS can be classified into three categories, including placenta accreta, placenta increta, and placenta percreta. Risk factors for PAS were identified as cesarean section (CS), hysteroscopy history, in vitro fertilization and embryo transfer and placenta previa, etc. It was reported that over 90% of the PAS cases were with prior cesarean delivery. In order to reduce the morbidity and mortality caused by PAS, guidelines were released from several international societies, including the Federation of Gynecology and Obstetrics (FIGO), Royal College of Obstetricians and Gynecologists (RCOG), the American College of Obstetricians and Gynecologists (ACOG) and Society of Obstetricians and Gynecologists of Canada (SOGC) recommending comprehensive multidisciplinary team (MDT) and expertise in pelvic and abdominal surgeries are essential for patients with PAS. Antenatal diagnosis of PAS is highly advisable, which is closely associated with surgery options, bleeding management and success of uterine preservation. Current diagnostic approaches include imaging examination, PAS prenatal grading system and MDT. Severe complications of PAS (particularly in the case of PP), such as substantial hemorrhage and organ injury, are closely related to the placental position and trophoblast invasion depth. Ultrasonography and MRI are major imaging means for prenatal diagnosis. In the meantime, to preserve fertility, approaches to conservative surgical management for PAS have been developed. The purpose for conservative management of PAS patients is to reduce bleeding, avoid organ injury, preserve the uterus and maintain uterine function. As the concept of uterine preservation is accepted by more and more practitioners, conservative surgical techniques have been developed accordingly. According to the survey of the Society for Maternal-Foetal Medicine (SMFM), only 15-32% of doctors would apply conservative management for PAS cases. Due to the lack of high-quality clinical trials as well as follow-up studies, standardized surgical management for PAS has not yet been determined. There are three approaches applied to placenta management in PAS, including manual separation of placenta, one-step conservative surgery and leaving the placenta in situ. Removing the complete placenta can effectively reduce bleeding and infection and preserve the uterus. The classical "Triple-P" management was proposed in 2012, which includes perioperative placental localization, pelvic devascularization and placental non-separation with myometrial excision and uterine reconstruction. The uterine artery tourniquet has numerous advantages, including a decrease in blood loss and the number of transfused packed RBC units. The simplicity of the technique allows for residents to apply the tourniquet to decrease the bleeding and allows time until an experienced obstetrician arrives. Presently, other attempts to avoid hysterectomy include uterine compression sutures, intrauterine balloon tamponade, pelvic artery ligation, and spiral suturing of the lower uterine segment. Intrauterine balloon tamponade may increase CS scar dehiscence, uterine rupture, and infection. Best practices for these methods involve skilled surgeons and obstetricians who have detailed knowledge of pelvic artery anatomy that includes vascular variations or distortions. The Apgar score was established in 1953 as a rapid newborn assessment immediately after birth. It provides a mechanism to describe the situation of the fetus becoming a newborn. Physicians face many challenges in analyzing the fetus' transition into a baby in the delivery room, especially for premature ones. The Apgar score is usually used to analyze the newborn after birth in the delivery room briefly. Thus, the Apgar score analyzes the clinical signs in neonates, such as cyanosis, pallor, bradycardia, decreased reflex response to stimulation, hypotonia, and apnea, or breathing problems such as abnormal rate and tachypnea as quantitative data. The Apgar score is reported at 1 and 5 min after birth and repeated every 5 min up to 20 min for infants with an Apgar score <7. A peculiar step of such a surgical approach involves the ligature of newly formed vessels between the uterus and the bladder. It has been speculated that such a step may affect the newborn by reducing blood flow to the placenta. This study aimed to report the neonatal outcome of women undergoing conservative reconstructive technique for PAS.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- randomized control trial formed of two groups group A receiving tourniquet group B control group
| Arm | Type | Receives |
|---|---|---|
| Tourniquet Group A | Active comparator | Procedure: Application Of A Tourniquet Around the lower segment of the uterusFoley catheter (20Fr) will be applied around the lower uterine segment at level lower than the placenta acting as a tourniquet The dissection of the utero-vesical fold will be extended laterally to both broad ligaments \& bilateral opening in the anterior leaflet of the broad ligament will be made. Both ureters will be identified beforehand. Foley catheter will be passed through the posterior leaflet of the left broad ligament in an avascular area, then passing the catheter back through Douglas pouch through the right broad ligament.The Foley catheter tourniquet will include both the lower uterine segment \& part of the bladder dome. supra-placental hysterotomy incision is carried out immediately after tightening the tourniquet followed by fetal extraction with immediate cord clamping (< 30 seconds).The uterus is then exteriorized, kept under upward traction so uterine vascular constriction can diminish blood loss \& the hysterotomy incision bleeding is temporarily control by towel clips |
| Non-Tourniquet group (B) | Placebo comparator | Procedure: Placenta Accreta spectrum conservative managementNo tourniquet is applied around the lower uterine segment: Same technique without adding a temporary tourniquet around the uterine artery. |
Who may qualify
- Ages
- 20 to 40 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Age: 20-40 years old.
- Pregnancy of a singleton living fetus.
- Gestational age: pregnancy completing 34 weeks or more.
- Previous one or more cesarean delivery.
- Current pregnancy complicated by Placena Accreta Spectrum Disorder candidate for conservative managment either total or partial Placenta Accreta.
Key exclusion criteria (3 listed)
- 1-Patients who refuse to participate in the study. 2-Women with history of a concomitant chronic or a pregnancy associated medical disorder eg. Gestational diabetes, hypertension, cardiac or renal disease.
- 3-Presence of a concomitant uterine pathology (eg. Uterine fibroid) 4-Premature rupture of membranes. 5-Cases misdiagnosed as placenta accreta by ultrasound preoperatively, and spontaneous full placental separation occurred intraoperative or as total/partial accreta and found to be focal accreta intraoperative.
- 6-Cases requiring preoperative blood transfusion. 7- Any fetal abnormality e.g IUGR or SGA
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Application Of A Tourniquet Around the lower segment of the uterusFoley catheter (20Fr) will be applied around the lower uterine segment at level lower than the placenta acting as a tourniquet The dissection of the utero-vesical fold will be extended laterally to both broad ligaments \& bilateral opening in the anterior leaflet of the broad ligament will be made. Both ureters will be identified beforehand. Foley catheter will be passed through the posterior leaflet of the left broad ligament in an avascular area, then passing the catheter back through Douglas pouch through the right broad ligament.The Foley catheter tourniquet will include both the lower uterine segment \& part of the bladder dome. supra-placental hysterotomy incision is carried out immediately after tightening the tourniquet followed by fetal extraction with immediate cord clamping (< 30 seconds).The uterus is then exteriorized, kept under upward traction so uterine vascular constriction can diminish blood loss \& the hysterotomy incision bleeding is temporarily control by towel clips | Procedure or surgery | Tourniquet Group A |
| Placenta Accreta spectrum conservative managementNo tourniquet is applied around the lower uterine segment: Same technique without adding a temporary tourniquet around the uterine artery. | Procedure or surgery | Non-Tourniquet group (B) |
Primary outcome
Neonatal Apgar Score
Time frame: 1 min and 5 mins after birth for all infants , and if after 5 mins score is less than 7 , scoring will continue every 5 mins till 20 mins
This scoring system provided a standardized assessment for infants after delivery. The Apgar score comprises five components: 1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is given a score of 0, 1, or 2. Thus, the Apgar score quantitates clinical signs of neonatal depression such as cyanosis or pallor, bradycardia, depressed reflex response to stimulation, hypotonia, and apnea or gasping respirations. The score is reported at 1 minute and 5 minutes after birth for all infants, and at 5-minute intervals thereafter until 20 minutes for infants with a score less than
11 secondary outcomes
Neonatal encephalopathy
Time frame: Immediately after birth
Gestational age
Time frame: preoperative
Birthweight
Time frame: immediately postoperative
Requirement for oxygen support
Time frame: immediately postoperative
NICU
Time frame: immediately postoperative
Early Neonatal Mortality
Time frame: one week
Operative time
Time frame: intraoperative
Incidence of bleeding
Time frame: perioperative and immediately postoperative
Incidence of complications
Time frame: intraoperative
Incidence of ICU admission
Time frame: immediately postoperative and up to 48 hours
Duration of hospital stay
Time frame: from 48 hours to 72 hours
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Feb 2026.
- Results publication- Obstetrics Subgroup SoOaG, Chinese Medical Association; Maternal and Fetal Medicine Special Committee of Obstetrics and Gynecology Branch of Chinese Medical Doctor Association. Guideline for diagnosis and treatment of placenta accreta spectrum disorders. Chinese Journal of Perinatal Medicine.2023;26(08):617-627.
- Results publication: PubMed 32698993Jauniaux E, Kingdom JC, Silver RM. A comparison of recent guidelines in the diagnosis and management of placenta accreta spectrum disorders. Best Pract Res Clin Obstet Gynaecol. 2021 Apr;72:102-116. doi: 10.1016/j.bpobgyn.2020.06.007. Epub 2020 Jun 27.
- Results publication: PubMed 33204176Morlando M, Collins S. Placenta Accreta Spectrum Disorders: Challenges, Risks, and Management Strategies. Int J Womens Health. 2020 Nov 10;12:1033-1045. doi: 10.2147/IJWH.S224191. eCollection 2020.
Related trials for Pregnancy
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Population Pharmacokinetics of Temocillin in Acute Enterobacterial Pyelonephritis in Children
Pyelonephritis
Active, not recruitingPhase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Carcinoma, Renal Cell
Recruiting
Safety and Performance of UCon Patch Electrode
Urinary Incontinence, Urinary Incontinence, Urge
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Application Of A Tourniquet Around the lower segment of the uterus and Placenta Accreta spectrum conservative management in people with Pregnancy and Placenta Accrete Spectrum, run by Kasr El Aini Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yassmine A Hamouda, MSC (00201001680580, yassmineamrabdelmegid@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Neonatal Apgar Score (time frame: 1 min and 5 mins after birth for all infants , and if after 5 mins score is less than 7 , scoring will continue every 5 mins till 20 mins). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07412925, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.